



Product images are not to scale and are for representation purposes only.

PrAbevmy® (Bevacizumab for injection) 25 mg/mL solution for dilution administered by IV infusion

Abevmy (bevacizumab) is a recombinant humanized monoclonal antibody available as single-use, preservative-free, clear glass vials with <u>latex-free</u>, butyl rubber stopper containing 25 mg/mL bevacizumab either as 100 mg bevacizumab in 4 mL or 400 mg bevacizumab in 16 mL.¹

PRODUCT	DIN	PACK SIZE	VIATRIS CODE	UPC CARTON	UPC VIAL
Abevmy 100 mg/4 mL	02522179	1 Vial	400556984	o 55873 10118 7	(01)00055873101187
Abevmy 400 mg/16 mL	02522160	1 Vial	400556986	0 "55873"10119" 4	(01)00055873101194

Reference: 1. Abevmy® [product monograph]. Canada: BGP Pharma ULC; 5 November 2021.



For more information on how to place an order (no minimum order quantity), contact Viatris Customer Service by phone on 1-800-575-1379 or by e-mail at customerservice.ca@viatris.com from Monday to Friday 8:30 am – 4:30 pm EST.



Abevmy Shipper & Carton Details

	ANTINEOPLASTIC AGENT				
Therapeutic Class	AHFS: 10:00.00 ANTINEOPLASTIC AGENTS				
	ATC: L01XC07 BEVACIZUMAB				
SKU Strength	100 mg/4 mL	400 mg/16 mL			
Carton Dimensions (L X W X H) mm	64 x 38 x 104 mm	87 x 43 x 90 mm			
Carton Weight Filled CT (gm)	45.5	69.5			
Shipper Case Dimension	560 X 355 X 210 mm	570 X 305 X 230 mm			
(L X W X H) mm	300 X 333 X 210 IIIIII				
Case Weight (kg)	5.9	6.3			
Cartons/Shipping Case	100 unit cartons per shipper	72 unit cartons per shipper			
Shipping & Storage Conditions	Refrigerated at 2–8 °C. Keep vial in the outer carton in order to protect from light. Do not freeze. Do not shake.				
Stability	Chemical and physical in-use stability has been demonstrated for 48 hours at 2 °C to 30 °C in 0.9% sodium chloride solution. No incompatibilities between Abevmy and polyvinyl chloride and polyolefin bags have been observed containing 0.9% w/v sodium chloride solution (saline) for injection.				
Price	\$347.85/vial	\$1,391.40/vial			



Viatris is committed to helping improve the lives of people in Canada by increasing their access to well-known, trusted medicines, helping them live healthier at every stage of life.

Viatris Advocate™ PSP Core Features:

- · Reimbursement navigation assistance
- · Financial assistance
- Bridging/compassionate use
- Access to private infusion clinics

All subject to patient enrollment and approval.

Viatris Advocate PSP Contact Information

Monday to Friday | 8:00 AM to 8:00 PM EST Phone: 1-833-847-4323 | Fax: 1-833-794-2382

E-mail: BiosimilarsCanada@innomarstrategies.com



For more information on Viatris' biosimilars, go to viatrisbiosimilars.ca For more information about Viatris, please visit viatris.ca

ABEVMY (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

ABEVMY, in combination with carboplatin/paclitaxel chemotherapy regimen, is indicated for treatment of patients with unresectable advanced, metastatic, or recurrent non-squamous non-small cell lung cancer.

ABEVMY, in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens.

ABEVMY, in combination with lomustine, is indicated for the treatment of patients with glioblastoma after relapse or disease progression, following prior therapy.

Pediatrics: the safety and efficacy of ABEVMY in patients under the age of 18 years have not been established.

Geriatrics: the risk and benefit of ABEVMY administration in patients > 65 should be carefully evaluated prior to initiating therapy. Pregnant women: ABEVMY should not be used during pregnancy.

Consult the Product Monograph at https://health-products.canada.ca/dpd-bdpp/index-eng.jsp for more information about conditions of clinical use, contraindications, warnings, precautions, adverse reactions, interactions and dosing. The Product Monograph is also available by calling 1-844-596-9526.

ABEVMY® is a registered trademark of Mylan Institutional Inc.; licensed use by BGP Pharma ULC, a Viatris company Viatris Advocate™ is a trademark of Mylan Inc., used under permission by BGP Pharma ULC, a Viatris company. VIATRIS and VIATRIS & Design are trademarks of Mylan Inc., used under permission by BGP Pharma ULC, a Viatris company. ©2022 Viatris Inc. All rights reserved. 85 Advance Road, Etobicoke, Ontario, M8Z 2S6 BEV-2021-0076E - AL2022

